Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failure
Ou Zhang1, Qingwei Ji1, Yingzhong Lin2
1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, The Key Laboratory of Remodeling-related Cardiovascular Disease, Ministry of Education, Beijing 100029, China.
Insights
Chemerin, a novel adipokine, is elevated in patients with dilated cardiomyopathy (DCM) and heart failure. Higher chemerin levels correlate with disease severity, suggesting it is a potential biomarker for DCM.
Area of Science:
- Cardiology
- Biochemistry
- Biomarkers
Background:
- Adipokines are linked to heart failure in ischemic heart disease and dilated cardiomyopathy (DCM).
- Plasma chemerin levels in DCM patients remain uninvestigated.
Purpose of the Study:
- To investigate plasma chemerin concentrations in DCM patients.
- To assess the correlation between chemerin and DCM severity indicators.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) measured plasma chemerin, IL-6, and TNF-α in 109 DCM patients and 60 controls.
- Echocardiography assessed left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF).
Main Results:
- DCM patients exhibited significantly higher plasma chemerin, IL-6, and TNF-α than controls.
- Chemerin positively correlated with IL-6, TNF-α, C-reactive protein (CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), and LVEDD.
- Chemerin negatively correlated with LVEF and was independently associated with DCM presence.
Conclusions:
- Chemerin is a novel biomarker for dilated cardiomyopathy (DCM).
- Elevated chemerin levels indicate increased DCM risk and severity.
Background:
Recent evidence demonstrated that the circulating concentrations of adipokine are related to the presence of heart failure secondary to ischemic heart disease and dilated cardiomyopathy (DCM). However, the plasma concentrations of chemerin in patients with DCM have yet to be investigated.
Methods:
The present study enrolled 109 DCM patients with typical symptoms of heart failure and 60 healthy controls and measured plasma concentrations of chemerin, IL-6 and TNF-α using enzyme-linked immunosorbent assay. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured using a GE ViVid E7 ultrasonography machine.
Results:
Plasma chemerin, IL-6 and TNF-α concentrations were significantly higher in DCM patients compared to the control group. A correlation analysis revealed that plasma chemerin concentrations were positively correlated with the concentrations of IL-6 (R=0.270, P=0.004), TNF-α (R=0.302, P=0.001), C-reactive protein (CRP) (R=0.256, P=0.004), N-terminal pro-brain natriuretic peptide (NT-proBNP) (R=0.386, P=0.000), and LVEDD (R=0.212, P=0.027) but negatively correlated with LVEF (R=-0.543, P=0.000). Furthermore, chemerin (OR 1.102, 95% CI 1.052 to 1.153; p=0.000) was independently associated with the presence of DCM before NT-proBNP was added in the multivariable regression model.
Conclusions:
The results indicate that chemerin is a novel biomarker of DCM.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Heart Failure II: Pathophysiology
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy